KEEGAN CROCKER: Open Payments
NPI 1639500739 · FISHERS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$359 in 22 payments from 8 companies in 2025. Trend: 2023 $546 · 2024 $514 · 2025 $359
Food & beverage: $359
| Company | Payments | Amount |
|---|---|---|
| Corium, LLC | 10 | $141 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| ABBVIE INC. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: Azstarys, REXULTI, Auvelity, HETLIOZ, VRAYLAR, Qelbree, CAPLYTA, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
